Antibody Information

General Information of This Antibody

Antibody ID	ANI0ZGVWE
Antibody Name	Anti-GPC1 mAb clone 01a033
Synonyms	Anti-GPC-1 mAb (clone 01a033) Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG2
Antigen Name	Glypican-1 (GPC1)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

GPC-1-ADC [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 22.63% (Day 28)	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	Tumour volumes reached >100 mm³, the mice were randomly divided into five groups (six per group). PBS, control ADC (10 mg/kg) or GPC-1-ADC (1 mg/kg) was injected from caudal veins every 4 days until four doses had been administered.
In Vivo Model	Pancreatic cancer PDX model
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.66% (Day 28)	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	Tumour volumes reached >100 mm³, the mice were randomly divided into five groups (six per group). PBS, control ADC (10 mg/kg) or GPC-1-ADC (3 mg/kg) was injected from caudal veins every 4 days until four doses had been administered.
In Vivo Model	Pancreatic cancer PDX model
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 69.22% (Day 28)	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	Tumour volumes reached >100 mm³, the mice were randomly divided into five groups (six per group). PBS, control ADC (10 mg/kg) or GPC-1-ADC (10 mg/kg) was injected from caudal veins every 4 days until four doses had been administered.
In Vivo Model	Pancreatic cancer PDX model

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 71.97% (Day 36)	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	Tumour-bearing mice were intravenously administered PBS, control ADC or GPC-1-ADC (1 mg/kg) on days 0, 4, 8 and 12.
In Vivo Model	BxPC-3 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 85.00% (Day 36)	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	Tumour-bearing mice were intravenously administered PBS, control ADC or GPC-1-ADC (3 mg/kg) on days 0, 4, 8 and 12.
In Vivo Model	BxPC-3 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.00% (Day 36)	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	Tumour-bearing mice were intravenously administered PBS, control ADC (10 mg/kg ) or GPC-1-ADC (10 mg/kg) on days 0, 4, 8 and 12, once every 4 days for a total of four doses.
In Vivo Model	BxPC-3 CDX model
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	IC50 of MMAF and anti-glypican-1 ADC in human pancreatic cancer cell lines.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.24 nM	Positive GPC-1 expression (GPC-1 +++/++)
Method Description	IC50 of MMAF and anti-glypican-1 ADC in human pancreatic cancer cell lines.
In Vitro Model	Pancreatic ductal adenocarcinoma	T3M-4 cells		CVCL_4056
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Negative GPC-1 expression (GPC-1 -)
Method Description	IC50 of MMAF and anti-glypican-1 ADC in human pancreatic cancer cell lines.
In Vitro Model	Pancreatic ductal adenocarcinoma	SUIT-2 cells		CVCL_3172

References

Ref 1	Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020 Apr;122(9):1333-1341. doi: 10.1038/s41416-020-0781-2. Epub 2020 Mar 10.